Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board
Nascent Biotech, Inc. (OTCQB:NBIO) announced the appointment of Dr. Ivan Babic to its scientific advisory board. Dr. Babic, with over 14 years of experience in translational oncology, is currently the Director of Gilman Biosciences. His background includes significant roles at UCLA, UCSD's Moores Cancer Center, and the John Wayne Cancer Institute, focusing on novel glioblastoma therapeutics. CEO Sean Carrick expressed enthusiasm about Dr. Babic's expertise contributing to the company's growth in developing monoclonal antibodies for cancer treatment.
- Appointment of Dr. Ivan Babic enhances the scientific advisory board's expertise.
- Dr. Babic brings over 14 years of oncology experience to the team.
- None.
VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting the treatment of various cancers, announced today that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board.
Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years.
Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma.
"We couldn't be more pleased that Dr. Babic has agreed to join our scientific advisory board," stated Sean Carrick, CEO of Nascent Biotech. "As we continue to build a top global team aspiring toward fresh milestones, Ivan adds critical expertise and a wealth of applied experience, and we are honored to welcome him into the fold."
About Nascent Biotech
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available.
For further information please visit our website www.nascentbiotech.com.
Safe Harbor: Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Corporate Contact
Sean Carrick | President | CEO | Nascent Biotech, Inc.
772.713.0541 Cell | sean.carrick@nascentbiotech.com
Public Relations
EDM Media, LLC
https://edm.media
SOURCE: Nascent Biotech Inc.
View source version on accesswire.com:
https://www.accesswire.com/732472/Nascent-Biotech-Announces-Appointment-of-Dr-Ivan-Babic-to-Scientific-Advisory-Board
FAQ
What does the appointment of Dr. Ivan Babic mean for Nascent Biotech (NBIO)?
What are Dr. Ivan Babic's qualifications?
How will Dr. Babic's experience benefit Nascent Biotech (NBIO)?
Who is the CEO of Nascent Biotech (NBIO)?
